Journal of Virus Eradication最新文献

{"title":"ST2.1 – 00087 A Novel HIV-1 Immune Evasion Strategy: How Softer HIV-1 Infected cells Preferentially Resist Cytotoxic T Lymphocytes (CTLs)","authors":"L. Leyre, F. Mustapha, A. Herrera, M. Huse, R.B. Jones","doi":"10.1016/j.jve.2024.100446","DOIUrl":"10.1016/j.jve.2024.100446","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 35-36"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial 10.4","authors":"","doi":"10.1016/j.jve.2024.100579","DOIUrl":"10.1016/j.jve.2024.100579","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"Article 100579"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B prevalence in an endemic area of hepatitis C virus: A population-based study implicated in hepatitis elimination in Thailand","authors":"Nawarat Posuwan ,&nbsp;Rujipat Wasitthankasem ,&nbsp;Napaporn Pimsing ,&nbsp;Wijittra Phaengkha ,&nbsp;Saranya Ngamnimit ,&nbsp;Preeyaporn Vichaiwattana ,&nbsp;Sirapa Klinfueng ,&nbsp;Maneerat Raksayod ,&nbsp;Yong Poovorawan","doi":"10.1016/j.jve.2024.100577","DOIUrl":"10.1016/j.jve.2024.100577","url":null,"abstract":"<div><div>Chronic hepatitis B (HBV) and C (HCV) are major health challenges in Thailand, with Phetchabun province, a known HCV-endemic area, being a key target for elimination efforts. This study aimed to assess HBV prevalence and identify associated risk factors in this province. Data was collected from three cross-sectional population studies: (1) adults in 2015 (n = 1,667, age 30–64 years), (2) young adults in 2017 (n = 1,453, age 18–30 years), both from high HCV-endemic districts, and (3) a province-wide study in 2018 (n = 4,769, age 35–64 years). Plasma samples were tested for HBsAg using the ARCHITECT assay. Results showed HBsAg seropositivity in 3.1 % of young adults in high-endemic districts, with significant associations with age, education, injecting drug use, and MSM behavior. Among adults, HBsAg prevalence was 5.9 %, linked to age and family liver disease history. Province-wide, 6.3 % of adults tested positive, with factors like gender and history of blood donation playing significant roles. Notably, age and blood donation were protective factors against HBV in adults. Analysis revealed a moderate HBV prevalence in those born before Thailand Expanded Program on Immunization (EPI) program, while those born after had rates below 1 %. The findings emphasize distinct HBV transmission patterns in different age groups, influenced by social and behavioral shifts. This knowledge is crucial for effective hepatitis elimination strategies in the Phetchabun province and nationwide.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"Article 100577"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients","authors":"Jiayi Wang ,&nbsp;Lingyao Du ,&nbsp;Dongmei Zhang ,&nbsp;Chen Zhou ,&nbsp;Yilan Zeng ,&nbsp;Miao Liu ,&nbsp;Xing Cheng ,&nbsp;Xiaona Song ,&nbsp;Han Chen ,&nbsp;Ning Han ,&nbsp;Enqiang Chen ,&nbsp;Hong Tang","doi":"10.1016/j.jve.2024.100571","DOIUrl":"10.1016/j.jve.2024.100571","url":null,"abstract":"<div><h3>Background</h3><div>Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. But real-world data on its effectiveness and safety remains scarce for patients with chronic hepatitis C (CHC) in China, especially those with HCV GT3b, cirrhosis, hepato-cellular carcinoma (HCC), or HCV/hepatitis B (HBV), HCV/HIV, or HCV/HBV/HIV coinfection.</div></div><div><h3>Methods</h3><div>In this real-world prospective observational study, we recruited patients from the West China Hospital and Public Health Clinical Center of Chengdu in China. Patients included adults with with CHC and any genotype (GT), with or without cirrhosis, hepatocellular carcinoma (HCC), HCV/HBV, HCV/HIV, or HCV/HBV/HIV coinfection. Patients were administered SOF/VEL (400/100 mg) ± ribavirin (RBV) once daily for 12 weeks. The primary efficacy endpoint was sustained virological response at post-treatment week 12 (SVR12). Adverse events (AEs) were evaluated during treatment.</div></div><div><h3>Results</h3><div>The study included 483 patients with HCV genotypes 1, 2, 3, 6 and uncertain ones. Among them, 35.4 % (171/483, ITT) and 36.7 % (166/452, mITT) received SOF/VEL + RBV. At the end of treatment , 99.2 % (ITT, 479/483) and 99.1 % (mITT, 448/452) of patients had undetectable HCV RNA. SVR12 rates were 92.8 % [intention to treat (ITT), 448/483] and 99.1 % [modified ITT (mITT), 448/452]. In the mITT analysis, SVR12 for patients with HCV GT3b, those with cirrhosis or HCC, and those coinfected with HBV/HIV was 99.2 % (130/131), 99.4 % (168/169), and 97.6 % (40/41), respectively. The albumin-bilirubin (ALBI) (−3.01 <em>vs.</em> −3.18 <em>P</em> &lt; 0.001), Fibrosis-4 (FIB4) Index (2.53 <em>vs.</em> 1.88, <em>P</em> = 0.004) and AST to Platelet Ratio Index (APRI) (0.99 <em>vs.</em> 0.44, <em>P</em> &lt; 0.001) scores showed a significant decrease from baseline to SVR12. No patients experienced grade 3–5 AEs.</div></div><div><h3>Conclusions</h3><div>Although a high proportion of patients included in this study had HCV GT3b, cirrhosis, HCC, or HCV/HBV, HCV/HIV, or HCV/HBV/HIV coinfection, SOF/VEL ± RBV was highly effective and well tolerated in Chinese patients with CHC.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"Article 100571"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6.1 – 00142 Durable Viral Load Remission in SHIV-infected Macaques after Vectored Delivery of Monoclonal Antibodies","authors":"J.M. Martinez-Navio,&nbsp;S.P. Fuchs,&nbsp;P.G. Mondragon,&nbsp;R. Zabizhin,&nbsp;D.E. Mendes,&nbsp;C.P.R. Muniz,&nbsp;K. Weisgrau,&nbsp;J. Furlott,&nbsp;E. Alexander,&nbsp;E.G. Rakasz,&nbsp;G. Gao,&nbsp;J.D. Lifson,&nbsp;R.C. Desrosiers","doi":"10.1016/j.jve.2024.100424","DOIUrl":"10.1016/j.jve.2024.100424","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 20-21"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP1.11 – 00021 Impact of HIV-1 Tat and TAR Sequence Diversity on Clinical and Reservoir Characteristics","authors":"M.R. Arikatla,&nbsp;N. Sonela,&nbsp;P. Khadka,&nbsp;Z. Tang,&nbsp;E. Benko,&nbsp;C. Kovacs,&nbsp;M. Caskey,&nbsp;R.M. Galiwango,&nbsp;T. Kityamuweesi,&nbsp;P. Buule,&nbsp;S. Tomusange,&nbsp;A. Anok,&nbsp;S.J. Reynolds,&nbsp;T.C. Quinn,&nbsp;J.L. Prodger,&nbsp;A.D. Redd,&nbsp;C. Muzoora,&nbsp;J.E. Haberer,&nbsp;J.N. Martin,&nbsp;D.R. Bangsberg,&nbsp;G.Q. Lee","doi":"10.1016/j.jve.2024.100460","DOIUrl":"10.1016/j.jve.2024.100460","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 46-48"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143131926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4.5 – 00020 Control of HIV infection is associated with enhanced CD8T cell functionality during consecutive analytical treatment interruptions","authors":"G. Duette,&nbsp;J. Marin-Rojas,&nbsp;S. Cronin,&nbsp;S.G. Deeks,&nbsp;A.D. Kelleher,&nbsp;S. Palmer","doi":"10.1016/j.jve.2024.100416","DOIUrl":"10.1016/j.jve.2024.100416","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 15-16"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2.3 – 00078 Detection of HIV-1 antisense transcripts in donor samples before and during ART","authors":"A. Capoferri,&nbsp;T.O. Famuyiwa,&nbsp;R. Sklutuis,&nbsp;S. Pathak,&nbsp;J.L. Groebner,&nbsp;R. Li,&nbsp;J.W. Rausch,&nbsp;S.G. Deeks,&nbsp;J.W. Mellors,&nbsp;J.M. Coffin,&nbsp;F. Romerio,&nbsp;M.F. Kearney","doi":"10.1016/j.jve.2024.100402","DOIUrl":"10.1016/j.jve.2024.100402","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Page 5"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP2.9 – 00007 HIV-PULSE as a newplatform to unveil HIV-1 reservoir composition: intactness, drug resistance, tropism and immune therapy predictions","authors":"S. De Braekeleer,&nbsp;L. Termote,&nbsp;S. Rutsaert,&nbsp;L. Lambrechts,&nbsp;W.A. Vos,&nbsp;A. Groenendijk,&nbsp;L. Van Eekeren,&nbsp;M. Blaauw,&nbsp;J. Stalenhoef,&nbsp;A. Verbon,&nbsp;M. Berrevoets,&nbsp;E. Blomme,&nbsp;M. Netea,&nbsp;A.J. Van Der Ven,&nbsp;S. Gerlo,&nbsp;L. Vandekerckhove","doi":"10.1016/j.jve.2024.100479","DOIUrl":"10.1016/j.jve.2024.100479","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Page 58"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP3.3 – 00121 Exploring the Effects of Benzodiazepines on a Novel Mechanism of Control in HIV-1 Infected Human Monocyte Derived Macrophages","authors":"C. Wallace,&nbsp;R. Van Duyne,&nbsp;P.J. Gaskill,&nbsp;Z. Klase","doi":"10.1016/j.jve.2024.100484","DOIUrl":"10.1016/j.jve.2024.100484","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 61-62"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143134583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}